67th ASH Annual Meeting and Exposition to Feature Analysis Group Research on Malignancies, Blood Disorders, and More

Survival and Clinical Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib: A Systematic Review and Meta-Analysis

December 6, 2025, 5:30–7:30 p.m.

Coauthors: Managing Principal James Signorovitch, Vice President Gautam Sajeev, Manager Mirko Fillbrunn, Associate Shuang Wang, and researchers from Moffitt Cancer Center; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”; Cleveland Clinic Taussig Cancer Institute; and GSK.

This study was sponsored by GSK.

Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Treated with Avapritinib Versus Real-World Therapy Based on Mutation-Adjusted Risk Score (MARS) Stratification

December 8, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Mei Sheng Duh, Vice President Priyanka Bobbili, Manager Aolin Wang, Senior Analyst Manasi Mohan, Analyst Anyu Zhu, and researchers from University Hospital Mannheim, Heidelberg University; Stanford Cancer Institute/Stanford University School of Medicine; Virgen del Valle Hospital; Guy’s & St Thomas’ NHS Foundation Trust of Guy’s Hospital; Blueprint Medicines; Dana-Farber Cancer Institute; Medical University of Vienna; and Necker-Enfants Malades Hospital.

This study was sponsored by Blueprint Medicines.

Real-World Incidence and Management of Non-ICANS Neurologic Events Following Ciltacabtagene Autoleucel in Multiple Myeloma

December 7, 2025, 6:00–8:00 p.m.

Coauthors: Vice President Bruno Émond, Manager Jessica Maitland, and researchers from Moffitt Cancer Center; Johnson & Johnson; Legend Biotech USA; and City of Hope.

This study was sponsored by Johnson & Johnson and Legend Biotech USA.

Treatment with Asciminib As a Second Line after One Prior Tyrosine Kinase Inhibitor (TKI) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) – A Chart Review Study in the United States

December 6, 2025, 5:30–7:30 p.m.

Coauthors: Vice President Jia Zhong, Manager Chelsey Yang, and researchers from the Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; and Tianjin Institutes of Health Science.

This study was sponsored by Takeda.

In-Class Transition from Bortezomib to Ixazomib-Based Regimens in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Retrospective, Observational, Real-World Study Conducted in China

Accepted in the abstract-only category  

Coauthors: Vice President Jia Zhong, Manager Chelsey Yang, and researchers from the Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; and Tianjin Institutes of Health Science.

This study was sponsored by Takeda.

Ixazomib Combined with Daratumumab-Based Regimens as First-Line Therapy for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Real-World Historical Database Analysis from China

Accepted in the abstract-only category  

Coauthors: Vice President Jia Zhong, Manager Chelsey Yang, and researchers from the Institute of Hematology & Blood Diseases Hospital; Chinese Academy of Medical Sciences & Peking Union Medical College; and Tianjin Institutes of Health Science.

This study was sponsored by Takeda.

Mortality Associated with Warm Autoimmune Hemolytic Anemia Among Medicare Beneficiaries

December 6, 2025, 5:30–7:30 p.m.

Coauthors: Vice Presidents Dominic Pilon and Masha Zhdanava, Associate Porpong Boonmak, Senior Analyst Grace Chen, Analyst Daisy Liu, and researchers from Johnson & Johnson and Mayo Clinic Hematology & Oncology (Johnson & Johnson sponsor).

Real-World Treatment Patterns and Clinical Outcomes of Therapies in Primary Immune Thrombocytopenia

December 8, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Hongbo Yang, Manager Su Zhang, Senior Analyst Jingyi Chen, Analyst Allister Ho, and researchers from University of Washington; Fred Hutch Cancer Center; and Novartis.

This study was sponsored by Novartis.

The Humanistic Burden of Patients with Chronic Myeloid Leukemia (CML) Treated with First-Line (1L) Tyrosine Kinase Inhibitors (TKIs)

December 8, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Nisha Hazra, Associate Yan Meng, and researchers from University of California; CML Buster Foundation; The Leukemia & Lymphoma Society; Novartis; Ipsos; and the Medical College of Wisconsin.

This study was sponsored by Novartis.

Real-World Treatment Patterns, Outcomes, and Unmet Needs in Patients with Ph+ ALL Receiving Tyrosine Kinase Inhibitors in the United States: Emerging Trends and the Role of Asciminib-Based Combinations

December 8, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Carmine Rossi, Associate Frédéric Kinkead, and researchers from Dana-Farber Cancer Institute; Novartis; and The University of Texas MD Anderson Cancer Center.

This study was sponsored by Novartis.

Real-World Analysis of Asciminib as First-Line Therapy in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Chart Review Study in the United States

Accepted in the abstract-only category

Coauthors: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Manager Carmine Rossi, Senior Research Professional Remi Bellefleur, and researchers from Novartis and the Medical College of Wisconsin.

This study was sponsored by Novartis.

Differences in Patient-Reported Time Toxicity Between Bispecific Antibody (BsAb) options: Impact of Treatment Duration and Dosing Frequency on Patient-Reported Time Burden in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL)

December 8, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Annie Guérin, Vice President Dominick Latrémouille-Viau, Associate Rebecca Bungay, and researchers from University of Colorado School of Medicine; Mayo Clinic; Fred Hutchinson Cancer Center; University of Washington; UT Health San Antonio MD Anderson Cancer Center; University of Wisconsin; Cancer Support Community; Memorial Sloan Kettering Cancer Center; and Genentech.

This study was sponsored by Genentech.

Patient Preferences and Factors Affecting Patient Treatment Decisions for Chronic Lymphocytic Leukemia (CLL) in Japan

December 7, 2025, 6:00–8:00 p.m.

Coauthors: Manager Todor Totev, Associate Yan Meng, Senior Analyst Zhuo Chen, and researchers from National Hospital Organization Osaka National Hospital; Koga Community Hospital; BeOne Medicines; and Mayo Clinic.

This study was sponsored by BeOne Medicines.

Evaluation of Venetoclax Initiation Prophylaxis and Monitoring Outcomes at Each Dose Level and Time Point in Patients with Chronic Lymphocytic Leukemia: A Real-World Experience

December 7, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Annie Guérin, Vice President Irina Pivneva, Senior Research Professional Talissa Watson, and researchers from Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill; Fred Hutchinson Cancer Research Center; University of Washington; Winship Cancer Institute of Emory University; Columbia University; AbbVie; Cleveland Clinic; Dana-Farber Cancer Institute; Churchill Hospital, Oxford University; Nottingham University Hospitals NHS Trust; John Theurer Cancer Center, Hackensack Meridian Health; Mayo Clinic; Wilmot Cancer Institute, University of Rochester Medical Center; Novant Health Cancer Institute; Stanford Cancer Institute, Stanford University; Memorial Sloan Kettering Cancer Center; Rutgers Cancer Institute of New Jersey; Hôpital Maisonneuve-Rosemont, University of Montreal; Dartmouth-Hitchcock Medical Center; Tufts Medical Center; Lowell General Hospital; University of Massachusetts; and Levine Cancer Institute / Atrium Health, Wake Forest University School of Medicine.

This study was sponsored by AbbVie.

Evaluating Patient Preferences for Chronic Lymphocytic Leukemia (CLL) in Korea: A Discrete Choice Experiment

Accepted in the abstract-only category   

Coauthors: Vice President Dominic Pilon, Associate Yan Meng, Senior Research Professional Fengyi Jiang, and researchers from Gachon University Gil Hospital; BeOne Medicines; and Mayo Clinic.

This study was sponsored by BeOne Medicines.

Real-World Treatment Characteristics and Outcomes in Patients with Von Willebrand Disease Treated Prophylactically with Plasma-Derived or Recombinant Von Willebrand Factor in Europe: A Multi-Center, Retrospective Study

December 7, 2025, 6:00–8:00 p.m.

Coauthors: Managing Principal Elyse Swallow, Vice President Irina Pivneva, Manager Sakshi Sethi, and researchers from IMD Blood Coagulation Center Hochtaunus; Bordeaux University Hospital; Haemostasis Clinical Center; Takeda; Lille University Hospital; Hannover Medical School; and Nantes University Hospital.

This study was sponsored by Takeda.

Real-World Treatment Patterns and Clinical Outcomes in Patients with Essential Thrombocythemia Treated with Cytoreductive Therapy: A Retrospective Analysis of Electronic Health Records Data

December 6, 2025, 5:30–7:30 p.m.

Coauthors: Managing Principal Mei Sheng Duh, Vice President Rose Chang, Vice President Priyanka Bobbili, Senior Analyst Louise Clear, Senior Analyst Zhuo Chen, Senior Analyst Yidan Ma, and researchers from Harvard Medical School; Dana-Farber Cancer Institute; Merck; Mass General Brigham; and Massachusetts General Hospital.

This study was sponsored by Merck.